RV 138

A study of Sanofi Pasteur live recombinant ALVAC-HIV Mar-06

WRAIR

US

(vCP205, HIV-1 env/gag/pol) administered subcutaneously

via ex vivo transfected, autologous dendritic cells,

intradermally or intramuscularly

HIVIS 02

A clinical trial to assess the safety and immunogenicity Jan-06

Karolinska Institute,

Sweden

of administering MVA, carrying HIV-1 genes env, gag,

SMI, USMHRP

and pol in volunteers who previously received plasmid

DNA with analogous HIV-1 genes in HIVIS 01

HVTN 064

A clinical trial to evaluate the safety and immunogenicity Jan-06

HVTN, NIAID,

US (3), Peru (2)

of recombinant protein vaccine EP-1043 and the DNA

Pharmexa-Epimmune

vaccine EP HIV-1090 given alone or in combination

IAVI D001

A randomized, placebo-controlled, dose-escalating, double- Dec-05

IAVI, Therion

India

blinded study to evaluate the safety and immunogenicity of

TBC-M4 MVA, HIV-1 multigenic subtype C vaccine

IAVI V001

A randomized, placebo-controlled, double-blind trial to Nov-05

IAVI, NIAID, VRC

Rwanda, Kenya

VRC 008

A clinical trial of a prime-boost HIV-1 vaccination schedule: Apr-04

NIAID, VRC

US

(05-I-0148)

multiclade DNA vaccine VRC-HIVDNA-016-00-VP, followed

by multiclade adenoviral vector vaccine, VRC-ADV-014-00-VP

evaluate the safety and immunogenicity of a multiclade

Boost: VRC-ADV-014-00-VP

env (A,B,C); gag,

HIV-1 DNA plasmid vaccine followed by recombinant,

pol (B), env (A,B,C)

multiclade HIV-1 adenoviral vector vaccine or the

multiclade HIV-1 adenoviral vector vaccine alone

HVTN 063

A clinical trial to evaluate the safety and immunogenicity

Sep-05

HVTN, NIAID, Wyeth

US (7), Brazil (2)

Prime: GENEVAX Gag-2692 +/-

gag (B); env, gag,

of HIV-1 Gag DNA vaccine alone or with IL-15 DNA,

IL-15 DNA

nef (B) or gag (B)

boosted with HIV-1 Gag DNA + IL-15 DNA or HIV-1

Boost: RC529-SE + GM-CSF or

Gag DNA + IL-12 DNA

GENEVAX Gag-2692 + IL-15

DNA or GENEVAX Gag-2692 +

IL-12 DNA

HVTN 060

A clinical trial to evaluate the safety and immunogenicity

Aug-05

HVTN, NIAID, Wyeth

US (3), Thailand

Prime: GENEVAX Gag-2692

gag (B); gag (B) or

of an HIV-1 Gag DNA vaccine with or without IL-12 DNA,

+/- IL-12 DNA

env, gag, nef (B)

boosted with homologous plasmids or with HIV CTL

Boost: DNA plasmids or

multiepitope peptide vaccine RC529-SE plus GM-CSF

RC529-SE + GM-CSF

RV 158/

A double-blind, randomized, dose escalating, placebo-

Jul-05

USMHRP, WRAIR, NIH

US

MVA-CMDR

gp160, gag, pol (A,E)

WR 1143

controlled, study of safety and immunogenicity of WRAIR/

Later: Thailand

NIH live recombinant MVA-CMDR (HIV-CM235 env/CM240

gag/pol) administered intramuscularly or intradermally

N/A

A randomized, placebo-controlled, double-blind trial to

Mar-05

Guangxi CDC

China

DNA Vaccine

DNA plasmids (B,C)

evaluate the safety and immunogenicity of a multiclade

HIV-1 DNA plasmid vaccine

EnvDNA

A clinical trial to evaluate the safety and tolerability of a

Feb-05

St. Jude; NIH

US

EnvDNA

env (A,B,C,D,E)

recombinant HIV-1 multi-envelope DNA plasmid vaccine

(EnvDNA)

EuroVacc 02

A clinical trial to evaluate the safety and immunogenicity

Feb-05

EuroVacc Foundation

Switzerland, UK

Prime: DNA-HIV-C

env, gag, pol, nef (C);

of DNA-HIV-C alone or DNA-HIV-C (prime) with

Boost: NYVAC-HIV-C

env, gag, pol, nef (C)

NYVAC-HIV-C (boost)

HIVIS 01

A clinical trial to assess the safety of different modes of

Feb-05

Karolinska Institute, SMI,

Sweden

HIVIS DNA

env (A,B,C), gag (A,B),

administering plasmid DNA with HIV genes env, rev,

Vecura

RT (B), rev (B)

gag, and RT

HVTN 049

A clinical trial to evaluate the safety and immunogenicity

Jan-05

HVTN, NIAID, Chiron

US (11)

Gag and Env DNA/PLG +

gag, env DNA/PLG,

of a Gag DNA/PLG and Env DNA/PLG microparticle

oligomeric gp140/MF59

oligomeric gp140 (B)

vaccine and gp140/MF59 adjuvant vaccine

IAVI C002

A randomized, placebo-controlled, dose-escalating, double-

Jan-05

IAVI, ADARC

US (2)

ADMVA

env/gag-pol, nef-tat (C)

blinded, study to evaluate the safety and immunogenicity of a

MVA expressing HIV-1 clade C env/gag-pol and nef-tat

fusion genes (ADMVA) vaccine

HVTN 055

A trial to evaluate the safety and immunogenicity of

Sep-04

HVTN, NIAID, Therion

US (4), Brazil (2)

TBC-M358(MVA); TBC-M335

env, gag (B); tat, rev, nef,

rMVAHIV and rFPHIV vaccines, alone or in combination

(MVA); TBC-F357(FPV);

RT (B); env, gag (B);

TBC-F349(FPV)

tat, rev, nef, RT (B)

RV 151/

A study of safety and immunogenicity of the WRAIR HIV-1

Jun-04

WRAIR, NIAID

US

LFn-p24

gag p24 protein (B)

WRAIR 984

vaccine LFn-p24, an anthrax-derived polypeptide,

adminstered intramuscularly with alyhydrogel adjuvant